Literature DB >> 30518549

Converter domain mutations in myosin alter structural kinetics and motor function.

Laura K Gunther1, John A Rohde2, Wanjian Tang1, Shane D Walton1, William C Unrath1, Darshan V Trivedi1, Joseph M Muretta2, David D Thomas2, Christopher M Yengo3.   

Abstract

Myosins are molecular motors that use a conserved ATPase cycle to generate force. We investigated two mutations in the converter domain of myosin V (R712G and F750L) to examine how altering specific structural transitions in the motor ATPase cycle can impair myosin mechanochemistry. The corresponding mutations in the human β-cardiac myosin gene are associated with hypertrophic and dilated cardiomyopathy, respectively. Despite similar steady-state actin-activated ATPase and unloaded in vitro motility-sliding velocities, both R712G and F750L were less able to overcome frictional loads measured in the loaded motility assay. Transient kinetic analysis and stopped-flow FRET demonstrated that the R712G mutation slowed the maximum ATP hydrolysis and recovery-stroke rate constants, whereas the F750L mutation enhanced these steps. In both mutants, the fast and slow power-stroke as well as actin-activated phosphate release rate constants were not significantly different from WT. Time-resolved FRET experiments revealed that R712G and F750L populate the pre- and post-power-stroke states with similar FRET distance and distance distribution profiles. The R712G mutant increased the mole fraction in the post-power-stroke conformation in the strong actin-binding states, whereas the F750L decreased this population in the actomyosin ADP state. We conclude that mutations in key allosteric pathways can shift the equilibrium and/or alter the activation energy associated with key structural transitions without altering the overall conformation of the pre- and post-power-stroke states. Thus, therapies designed to alter the transition between structural states may be able to rescue the impaired motor function induced by disease mutations.
© 2019 Gunther et al.

Entities:  

Keywords:  ATPase; actin; cardiomyopathy; fluorescence resonance energy transfer (FRET); mechanochemistry; motor protein; muscle; myosin; structural kinetics

Mesh:

Substances:

Year:  2018        PMID: 30518549      PMCID: PMC6364761          DOI: 10.1074/jbc.RA118.006128

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  69 in total

Review 1.  Hypertrophic cardiomyopathy.

Authors:  Barry J Maron; Martin S Maron
Journal:  Lancet       Date:  2012-08-06       Impact factor: 79.321

2.  Multidimensional structure-function relationships in human β-cardiac myosin from population-scale genetic variation.

Authors:  Julian R Homburger; Eric M Green; Colleen Caleshu; Margaret S Sunitha; Rebecca E Taylor; Kathleen M Ruppel; Raghu Prasad Rao Metpally; Steven D Colan; Michelle Michels; Sharlene M Day; Iacopo Olivotto; Carlos D Bustamante; Frederick E Dewey; Carolyn Y Ho; James A Spudich; Euan A Ashley
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-31       Impact factor: 11.205

3.  Determination of the dead time of a stopped-flow fluorometer.

Authors:  P Brissette; D P Ballou; V Massey
Journal:  Anal Biochem       Date:  1989-09       Impact factor: 3.365

4.  A Perspective on the Role of Myosins as Mechanosensors.

Authors:  Michael J Greenberg; Göker Arpağ; Erkan Tüzel; E Michael Ostap
Journal:  Biophys J       Date:  2016-06-21       Impact factor: 4.033

5.  Direct measurements of the coordination of lever arm swing and the catalytic cycle in myosin V.

Authors:  Darshan V Trivedi; Joseph M Muretta; Anja M Swenson; Jonathon P Davis; David D Thomas; Christopher M Yengo
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-09       Impact factor: 11.205

6.  Omecamtiv Mecarbil modulates the kinetic and motile properties of porcine β-cardiac myosin.

Authors:  Yingying Liu; Howard D White; Betty Belknap; Donald A Winkelmann; Eva Forgacs
Journal:  Biochemistry       Date:  2015-03-04       Impact factor: 3.162

7.  Purification of muscle actin.

Authors:  J D Pardee; J A Spudich
Journal:  Methods Enzymol       Date:  1982       Impact factor: 1.600

8.  Structural mechanism of the recovery stroke in the myosin molecular motor.

Authors:  Stefan Fischer; Björn Windshügel; Daniel Horak; Kenneth C Holmes; Jeremy C Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-29       Impact factor: 11.205

9.  Hypertrophic and dilated cardiomyopathy mutations differentially affect the molecular force generation of mouse alpha-cardiac myosin in the laser trap assay.

Authors:  Edward P Debold; J P Schmitt; J B Patlak; S E Beck; J R Moore; J G Seidman; C Seidman; D M Warshaw
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-03-09       Impact factor: 4.733

10.  A 35-A movement of smooth muscle myosin on ADP release.

Authors:  M Whittaker; E M Wilson-Kubalek; J E Smith; L Faust; R A Milligan; H L Sweeney
Journal:  Nature       Date:  1995-12-14       Impact factor: 49.962

View more
  7 in total

1.  FRET and optical trapping reveal mechanisms of actin activation of the power stroke and phosphate release in myosin V.

Authors:  Laura K Gunther; John A Rohde; Wanjian Tang; Joseph A Cirilo; Christopher P Marang; Brent D Scott; David D Thomas; Edward P Debold; Christopher M Yengo
Journal:  J Biol Chem       Date:  2020-12-18       Impact factor: 5.157

2.  FRET and optical trapping reveal mechanisms of actin-activation of the power stroke and phosphate-release in myosin V.

Authors:  Laura K Gunther; John A Rohde; Wanjian Tang; Joseph A Cirilo; Christopher P Marang; Brent D Scott; David D Thomas; Edward P Debold; Christopher M Yengo
Journal:  J Biol Chem       Date:  2020-10-14       Impact factor: 5.157

3.  Dilated cardiomyopathy mutation in the converter domain of human cardiac myosin alters motor activity and response to omecamtiv mecarbil.

Authors:  Wanjian Tang; William C Unrath; Rohini Desetty; Christopher M Yengo
Journal:  J Biol Chem       Date:  2019-10-02       Impact factor: 5.157

4.  Muscle LIM Protein Force-Sensing Mediates Sarcomeric Biomechanical Signaling in Human Familial Hypertrophic Cardiomyopathy.

Authors:  Muhammad Riaz; Jinkyu Park; Lorenzo R Sewanan; Yongming Ren; Jonas Schwan; Subhash K Das; Pawel T Pomianowski; Yan Huang; Matthew W Ellis; Jiesi Luo; Juli Liu; Loujin Song; I-Ping Chen; Caihong Qiu; Masayuki Yazawa; George Tellides; John Hwa; Lawrence H Young; Lei Yang; Charles C Marboe; Daniel L Jacoby; Stuart G Campbell; Yibing Qyang
Journal:  Circulation       Date:  2022-04-06       Impact factor: 39.918

5.  Cardiomyopathy mutations impact the actin-activated power stroke of human cardiac myosin.

Authors:  Wanjian Tang; Jinghua Ge; William C Unrath; Rohini Desetty; Christopher M Yengo
Journal:  Biophys J       Date:  2021-04-20       Impact factor: 3.699

6.  Impact of regulatory light chain mutation K104E on the ATPase and motor properties of cardiac myosin.

Authors:  David V Rasicci; Orville Kirkland; Faruk H Moonschi; Neil B Wood; Danuta Szczesna-Cordary; Michael J Previs; Jonathan F Wenk; Kenneth S Campbell; Christopher M Yengo
Journal:  J Gen Physiol       Date:  2021-07-05       Impact factor: 4.086

7.  Structural and Computational Insights into a Blebbistatin-Bound Myosin•ADP Complex with Characteristics of an ADP-Release Conformation along the Two-Step Myosin Power Stoke.

Authors:  Wiebke Ewert; Peter Franz; Georgios Tsiavaliaris; Matthias Preller
Journal:  Int J Mol Sci       Date:  2020-10-08       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.